Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 8, Issue 4, 2004, Pages 448-453

  Wilkinson, Neal W ^a,b   Black, Jennifer D ^a   Roukhadze, Elena ^a   Driscoll, Deborah ^a   Smiley, Shannon ^a   Hoshi, Hisakazu ^a   Geradts, Joseph ^a   Javle, Milind ^a   Brattain, Michael ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

epidermal growth factor receptor; Esophageal adenocarcinoma; immunohistochemical analysis; tyrosine kinase receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; ESOPHAGOGASTROSTOMY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MALE; PREOPERATIVE RADIOTHERAPY; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 2342437556     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2004.01.006     Document Type: Article

References (28)

1. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212
2. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410:1997;83-86
3. Klapper L.N., Kirschbaum M.H., Sela M., Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 77:2000;25-79
4. Lemmon M.A., Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci. 19:1994;459-463
5. Schlessinger J. The epidermal growth factor receptor as a multifunctional allosteric protein. Biochemistry. 27:1988;3119-3123
6. Gullick W.J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 47:1991;87-98
7. Kim E.S. Epidermal growth factor receptor as a target in gene therapy. J Natl Comp Cancer Net. 1:(Suppl):2003;S87-S95
8. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer. 37:(Suppl 4):2001;S9-S15
9. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer. 37:(Suppl 4):2001;S16-S22
10. Hao D., Rowinsky E.K. Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors. Cancer Invest. 20:2002;387-404
11. al-Kasspooles M., Moore J.H., Orringer M.B., Beer D.G. Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 54:1993;213-219
12. Jankowski J., Hopwood D., Wormsley K.G. Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. Dig Dis. 11:1993;1-11
13. Poller D.N., Steele R.J., Morrell K. Epidermal growth factor receptor expression in Barrett's esophagus. Arch Pathol Lab Med. 116:1992;1226-1227
14. Yacoub L., Goldman H., Odze R.D. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod Pathol. 10:1997;105-112
15. Watanabe G., Kaganoi J., Imamura M., Shimada Y., Itami A., Uchida S., Sato F., Kitagawa M. Progression of esophageal carcinoma by loss of EGF-STAT1 pathway. Cancer J. 7:2001;132-139
16. Jankowski J., Murphy S., Coghill G., Grant A., Wormsley K.G., Sanders D.S., Kerr M., Hopwood D. Epidermal growth factor receptors in the oesophagus. Gut. 33:1992;439-443
17. Calabro A., Orsini B., Renzi D., Papi L., Surrenti E., Amorosi A., Herbst H., Milani S., Surrenti C. Expression of epidermal growth factor, transforming growth factor-alpha and their receptor in the human oesophagus. Histochem J. 29:1997;745-758
18. Krishnadath K.K., Reid B.J., Wang K.K. Biomarkers in Barrett Esophagus. Mayo Clin Proc. 76:2001;438-446
19. Kelloff G.J., Fay J.R., Steele V.E., Lubert R.A., Boone C.W., Crowell J.A., Sigman C.C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 5:1996;657-666
20. Jenkins G.J., Doak S.H., Parry J.M., D'Souza F.R., Griffiths A.P., Baxter J.N. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg. 89:2002;824-837
21. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics. CA Cancer J Clin. 53:2003;5-26
22. Ozawa S., Ueda M., Ando N., Shimizu N., Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer. 63:1989;2169-2173
23. Cooper J.S., Guo M.D., Herskovic A., MacDonald J.S., Martenson J.A. Jr., Al-Sarraf M., Byhardt R., Russell A.H., Beitler J.J., Spencer S., Asbell S.O., Graham M.V., Leichman L.L. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281:1999;1623-1627
24. Yasui W., Hata J., Yokozaki H., Nakatani H., Ochiai A., Ito H., Tahara E. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer. 41:1988;211-217
25. Garcia I., Vizoso F., Martin A., Sanz L., Abdel-Lah O., Raigoso P., Garcia-Muniz J.L. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 10:2003;234-241
26. Tsujino T., Yoshida K., Nakayama H., Ito H., Shimosato T., Tahara E. Alterations of oncogenes in metastatic tumours of human gastric carcinomas. Br J Cancer. 62:1990;226-230
27. Arteaga C.L., Johnson D. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 13:2001;491-498
28. Huang S.M., Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale, and preliminary clinical results. Invest New Drugs. 17:1999;259-269